The FDA Approves Mozobil - Helps Boost Stem Cells before Treatment of Non-Hodgkin’s Lymphoma
The FDA Approved Mozobil from Genzyme to be used in patients with Non-Hodgkin's Lymphoma. The purpose of the drug is to boost a person's stem cell count before the patient gets a bone marrow transplant. The approval from the FDA was based on a clinical study where 59% of NHL patients who were on Mozobil collected the target amount of stem cells (5 million per kg of body weight) versus just 20% of NHL patients on Placebo. The drug will be available in the first quarter of 2009.